CRISPR-Cas9 potential in treating HIV/AIDS
DOI:
https://doi.org/10.54097/5gars203Keywords:
Gene editing, HIV/AIDS, CRISPR-Cas9, co-receptors.Abstract
In this review paper, the mechanism of HIV infection and some of the most efficacious and updated gene therapy methods developed by scientists will be discussed in detail. Different editing strategy using the CRISPR-Cas9 system inhibits different times of the HIV life cycle are involved with all the same target, which is to block the HIV infection pathway as well as its own replication&proliferation pathway. As the most popular and promising way of treating different kinds of diseases which seemed to be incurable in the past, and CRISPR-Cas9 shows high potency under the data of experiments and clinical studies. These give scientists many confidence to run out more research on this new treatment for diseases and at the same time to improve and optimize the function and efficiency of this gene editing toolkit making sure it can used widely in the future as an actual clinical treatment for the HIV/AIDS.
Downloads
References
Fuguo Jiang; Jennifer A. Doudna CRISPR-Cas9 structures and mechanism Available online: https://www.annualreviews.org/doi/full/10.1146/annurev-biophys-062215-010822
Jennifer A. Doudna; Emmanule Charpentier The new frontier of genome engineering with CRISPR-Cas9. Available online: https://www.science.org/doi/abs/10.1126/science.1258096
World Health Organization: HIV and AIDS. Available online: https://www.who.int/news-room/fact-sheets/detail/hiv-aids?gclid=EAIaIQobChMI1Z-V0cfWgAMVutIWBR1sUwn4EAAYASAAEgIaAfD_BwE
Simon.J.Potter; Choo Beng Chew; Megan Steain et al. Obstacles to successful antiretroviral treatment of HIV-1 infection: problems&perspectives. Available online: https://www.researchgate.net/profile/Megan-Steain/publication/8466405_Obstacles_to_successful_antiretroviral_treatment_of_HIV-1_infection_Problems_and_perspectives/links/0912f50e41919ce2a9000000/Obstacles-to-successful-antiretroviral-treatment-of-HIV-1-infection-Problems-and-perspectives.pdf
Amanda R.Panfil; James A.London; Patrick L.Green and Kristine E.Yoder. CRISPR/Cas9 genome editing to disable the latent HIV-1 provirus. Available online: https://www.frontiersin.org/articles/10.3389/fmicb.2018.03107/full
Hsin-Kai Liao; Ying Gu; Arturo Diaz; Yuta Takahashi et al. Use of the CRISPR-Cas9 system as and intracellular defense against HIV-1 infection in human cells. Available online: https://www.nature.com/articles/ncomms7413
Nature review microbiology: Schematic overview of the HIV-1 replication cycle. Available online: https://www.nature.com/articles/nrmicro2747/figures/1
Alexander G.Allen; Cheng-Han Chung; Andrew Atkins et al. Gene editing of HIV-1 co-receptors to prevent and/or cure virus infection. Available online: https://www.frontiersin.org/articles/10.3389/fmicb.2018.02940/full
Zhepeng Liu; Shuliang Chen; Xu Jin; Qiankun Wang et al. Genome editing of the HIV co-receptors CCR5 and CXCR4 by CRISPR-Cas9 protects CD4+ T cells from HIV-1 infection. Available online: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5591563/
Songlin Yu; Yongchao Yao; Hongkui Xiao et al. Simultaneous knockout of CXCR4 and CCR5 genes in CD4+ T cells via CRISPR-Cas9 confers resistance to both X4- and R5- tropic human immunodeficiency virus type 1 infection. Available online: https://www.liebertpub.com/doi/full/10.1089/hum.2017.032
Andrew Atkins, Cheng-Han Chung, Alexander G.Allen, Will Dampier: Off-Target analysis in gene editing and applications for clinical translation of CRISPR/Cas9 in HIV-1 therapy. Available online: https://www.frontiersin.org/articles/10.3389/fgeed.2021.673022/full
Shengdar Q. Tsai, Nhu T Nguyen, Jose Malagon-Lopez et al: CIRCLE-seq: a highly sensitive in vitro screen for genome-wide CRISPR-Cas9 nuclease off-targets. Available online: https://www.nature.com/articles/nmeth.4278
Cicera R. Lazzarotto, Nhu T. Nguyen, Xing Tang et al: Defining CRISPR-Cas9 genome-wide nuclease activities with CIRCLE-seq. Available online: https://www.nature.com/articles/s41596-018-0055-0
Hirotake Ebina; Naoko Misawa; Yuka kanemura; Yoshio koyanagi. Harnessing the CRISPR-Cas9 system to disrupt latent HIV-1 provirus. Available online: https://www.nature.com/articles/srep02510
Tara p. Hurst; Gklkas Magiorkinis. Epigenetic control of human endogenous retrovirus expression: Focus on regulation of Long-terminal repeats (LTRs). Available online: https://www.mdpi.com/1999-4915/9/6/130
Cheng-Han Chung; Alexander G.Allen; Andrew J. Atkins et al. Safe CRISPR-Cas9 Inhibition of HIV-1 with high specificity and broad-spectrum by targeting LTR NF-kB binding sites. Available online: https://www.cell.com/molecular-therapy-family/nucleic-acids/fulltext/S2162-2531(20)30205-5
Lei Xu, Jun Wang, Yulin Liu, Liangfu Xie, Bin Su et al. CRISPR-Edited stem cells in a patient with HIV and Acute Lymphocytic leukemia.
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
